ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?

Zacks11-12

Have you been paying attention to shares of Adma Biologics (ADMA)? Shares have been on the move with the stock up 37.3% over the past month. The stock hit a new 52-week high of $23.64 in the previous ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483080948?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QOfludHza1dTKV8R6Coeiw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/48ad4265c55e3ba7a1fb9148d6e717d9","is_english":true,"pubTime":"2024-11-12 22:15","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483080948","market":"us","top_or_hot":-1,"title":"ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?","media":"Zacks","content":"<div>\n<p>Have you been paying attention to shares of Adma Biologics (ADMA)? Shares have been on the move with the stock up 37.3% over the past month. The stock hit a new 52-week high of $23.64 in the previous ...</p>\n\n<a href=\"https://finance.yahoo.com/news/adma-biologics-inc-adma-hits-141511648.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-12 22:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/adma-biologics-inc-adma-hits-141511648.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Have you been paying attention to shares of Adma Biologics (ADMA)? Shares have been on the move with the stock up 37.3% over the past month. The stock hit a new 52-week high of $23.64 in the previous ...</p>\n\n<a href=\"https://finance.yahoo.com/news/adma-biologics-inc-adma-hits-141511648.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/adma-biologics-inc-adma-hits-141511648.html","article_id":"2483080948","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QOfludHza1dTKV8R6Coeiw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/48ad4265c55e3ba7a1fb9148d6e717d9"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483080948","pubTimestamp":1731420911,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Have you been paying attention to shares of Adma Biologics ?Shares have been on the move with the stock up 37.3% over the past month. The stock hit a new 52-week high of $23.64 in the previous session. Adma Biologics has gained 397.4% since the start of the year compared to the 4.7% move for the Zacks Medical sector and the 0.7% return for the Zacks Medical - Biomedical and Genetics industry.The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on November 7, 2024, Adma Biologics reported EPS of $0.15 versus consensus estimate of $0.13 while it beat the consensus revenue estimate by 11.74%.For the current fiscal year, Adma Biologics is expected to post earnings of $0.52 per share on $425.6 million in revenues. Meanwhile, for the next fiscal year, the company is expected to earn $0.77 per share on $492.67 million in revenues. This represents a year-over-year cha","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4532":"文艺复兴科技持仓","ADMA":"ADMA Biologics Inc","EXEL":"伊克力西斯"},"translate_title":"ADMA Biologics Inc(ADMA)再创新高：还有上涨空间吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1,"EXEL":0.9},"content_text":"Have you been paying attention to shares of Adma Biologics (ADMA)? Shares have been on the move with the stock up 37.3% over the past month. The stock hit a new 52-week high of $23.64 in the previous session. Adma Biologics has gained 397.4% since the start of the year compared to the 4.7% move for the Zacks Medical sector and the 0.7% return for the Zacks Medical - Biomedical and Genetics industry.\nWhat's Driving the Outperformance?\nThe stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on November 7, 2024, Adma Biologics reported EPS of $0.15 versus consensus estimate of $0.13 while it beat the consensus revenue estimate by 11.74%.\nFor the current fiscal year, Adma Biologics is expected to post earnings of $0.52 per share on $425.6 million in revenues. Meanwhile, for the next fiscal year, the company is expected to earn $0.77 per share on $492.67 million in revenues. This represents a year-over-year change of 49.68% and 15.76%, respectively.\nValuation Metrics\nAdma Biologics may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself.\nOn this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.\nAdma Biologics has a Value Score of D. The stock's Growth and Momentum Scores are A and D, respectively, giving the company a VGM Score of B.\nIn terms of its value breakdown, the stock currently trades at 43.5X current fiscal year EPS estimates, which is a premium to the peer industry average of 25.4X. On a trailing cash flow basis, the stock currently trades at 442.4X versus its peer group's average of 18X. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.\nZacks Rank\nWe also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, Adma Biologics currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.\nSince we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Adma Biologics fits the bill. Thus, it seems as though Adma Biologics shares could have potential in the weeks and months to come.\nHow Does ADMA Stack Up to the Competition?\nShares of ADMA have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is Exelixis, Inc. (EXEL). EXEL has a Zacks Rank of # 2 (Buy) and a Value Score of B, a Growth Score of A, and a Momentum Score of B.\nEarnings were strong last quarter. Exelixis, Inc. beat our consensus estimate by 11.90%, and for the current fiscal year, EXEL is expected to post earnings of $1.99 per share on revenue of $2.16 billion.\nShares of Exelixis, Inc. have gained 37.9% over the past month, and currently trade at a forward P/E of 18.87X and a P/CF of 46.99X.\nThe Medical - Biomedical and Genetics industry is in the top 29% of all the industries we have in our universe, so it looks like there are some nice tailwinds for ADMA and EXEL, even beyond their own solid fundamental situation.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nADMA Biologics Inc (ADMA) : Free Stock Analysis Report\nExelixis, Inc. (EXEL) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483080948"}